Pharmacy-based STI testing draws strong support in urban Uganda
Private community pharmacies already serve as the first stop for many people with genital symptoms, and that reality shaped the discussion around point-of-care and near-point-of-care testing for sexually transmitted infections in Kampala and Wakiso districts. When diagnostic testing is out of reach, treatment often becomes empiric, which can mean missed infections, delayed partner management, and unnecessary antibiotic exposure. In this qualitative study nested within a prospective cohort, clients, health care providers, and policymakers largely viewed pharmacy-based testing as a workable way to narrow those gaps.
Convenience mattered, but so did speed. The appeal of getting tested where people already seek help is straightforward: fewer referrals, less travel, and faster answers before symptoms drive patients deeper into the health system or toward self-medication.
Acceptability was high across clients, providers, and policymakers
The qualitative sample included 50 participants interviewed between June and September 2022, with 35 clients, 9 health care providers, and 6 policymakers contributing perspectives. Their responses aligned around a common theme: POC/near-POC STI testing in community pharmacies was seen as affordable, accessible, and convenient. For clients, those features carried obvious practical value in settings where laboratory diagnostics can be expensive or geographically difficult to reach. For providers and policymakers, the same features suggested a more realistic path toward earlier diagnosis and better-targeted treatment.
The testing package included HIV, syphilis, trichomonas, chlamydia, and gonorrhea. That mix matters clinically because symptoms alone do not reliably distinguish among these infections, and syndromic treatment can miss asymptomatic disease while exposing some patients to unnecessary drugs. Near-patient testing changes the clinical sequence: diagnosis comes before treatment, and treatment can then follow a specific result rather than a broad guess.
Participants also connected testing with behavior change. Receiving an immediate or near-immediate result may make risk feel more concrete, especially when combined with counseling at the point of care. In sexual health, a rapid diagnosis can do more than confirm infection; it can create a narrow but critical window for partner notification, treatment adherence, and safer sex counseling.
Faster results and better stewardship were recurring themes
A repeated advantage was the shorter turnaround time compared with conventional laboratory pathways. In a setting where patients may not return for a second visit, the ability to test and act during the same encounter can change what happens next. For suspected bacterial STIs, that speed also intersects with antimicrobial stewardship. When the cause of symptoms is identified more precisely, treatment can be focused rather than empiric, reducing avoidable antibiotic exposure and supporting control of resistance patterns.
Several participants linked pharmacy-based testing with sustainable antimicrobial resistance control. Their reasoning was clinically sound: broad, repeated empiric treatment in community settings can promote resistance, while diagnostics can curb unnecessary prescribing. That logic is especially relevant for gonorrhea, where resistance has long complicated treatment choices and where diagnostic confirmation helps anchor management.
Still, implementation was not treated as automatic. Acceptability did not erase the operational problems that surfaced in the interviews.
Privacy, stigma, and workflow barriers could limit uptake
Privacy emerged as a major concern. Community pharmacies are busy spaces, and inadequate private rooms or cramped layouts can discourage people from seeking testing for infections tied to sexual behavior and stigma. HIV testing carried particular sensitivity, but reluctance also extended to non-HIV STIs, showing how embarrassment and fear can suppress demand even when services are nearby.
Long waiting times created another friction point. A service designed for speed loses appeal when the process becomes slow or cumbersome, especially in a retail environment where patients expect quick transactions. Unclear instructions for self-sample collection added to the problem, suggesting that the technical simplicity of some near-POC tools does not automatically translate into user confidence.
Limited awareness among both clients and health workers also constrained uptake. If people do not know tests are available, or if providers are not comfortable explaining them, diagnostic services remain underused even when they are physically present. In practice, information gaps can be as limiting as supply gaps.
Training, supply chains, and public messaging were seen as essential
Participants recommended raising STI awareness, improving explanations of test results, expanding access, reducing stigma, training providers, and ensuring a sustainable supply chain for testing kits. Each recommendation addresses a different point of failure in the care pathway. Awareness drives demand. Training improves service quality and counseling. Reliable kit supply prevents interruptions that can quickly erode trust.
Clearer result communication may be especially important in community pharmacy settings. Rapid tests only help if clients understand what a positive or negative result means, what treatment should follow, and whether referral is needed. Without that clarity, a fast result can still lead to confusion or incomplete care.
For policymakers, the appeal lies in system design. Community pharmacies already absorb a large share of first-contact sexual health care. Embedding diagnostic testing in that setting could extend reach without waiting for patients to present at higher-level facilities. The study’s findings point to a service model that is already socially acceptable and operationally intuitive, provided the supporting infrastructure is in place.
A workable entry point for national HIV and STI programs
The central message from this Uganda study is direct: community pharmacy-based HIV/STI testing was highly acceptable to clients, providers, and policymakers, and it was viewed as a practical route to faster treatment and better linkage to care. The promise lies in matching diagnostics to the place where patients already seek help.
One important constraint remains embedded in the implementation details. Privacy, staffing, patient instruction, and supply continuity all have to function at the same time, and any weak link can blunt uptake. The study adds qualitative support for pharmacy-based testing, but it also makes clear that expansion will depend on whether the health system can support the service as reliably as it supports the test itself.